CN113631725A - 用于诊断和治疗目的的对外排体相关微生物组的分离和检测 - Google Patents

用于诊断和治疗目的的对外排体相关微生物组的分离和检测 Download PDF

Info

Publication number
CN113631725A
CN113631725A CN202080024007.0A CN202080024007A CN113631725A CN 113631725 A CN113631725 A CN 113631725A CN 202080024007 A CN202080024007 A CN 202080024007A CN 113631725 A CN113631725 A CN 113631725A
Authority
CN
China
Prior art keywords
cancer
microbial
patient
disease
microbiome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080024007.0A
Other languages
English (en)
Chinese (zh)
Inventor
拉古·卡尔卢里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN113631725A publication Critical patent/CN113631725A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202080024007.0A 2019-02-08 2020-02-07 用于诊断和治疗目的的对外排体相关微生物组的分离和检测 Pending CN113631725A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802994P 2019-02-08 2019-02-08
US62/802,994 2019-02-08
PCT/US2020/017224 WO2020163724A1 (en) 2019-02-08 2020-02-07 Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes

Publications (1)

Publication Number Publication Date
CN113631725A true CN113631725A (zh) 2021-11-09

Family

ID=71947984

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080024007.0A Pending CN113631725A (zh) 2019-02-08 2020-02-07 用于诊断和治疗目的的对外排体相关微生物组的分离和检测

Country Status (8)

Country Link
US (1) US20220137056A1 (https=)
EP (1) EP3921325A4 (https=)
JP (1) JP2022519326A (https=)
KR (1) KR20210125532A (https=)
CN (1) CN113631725A (https=)
AU (1) AU2020218358A1 (https=)
CA (1) CA3129250A1 (https=)
WO (1) WO2020163724A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114486829A (zh) * 2022-01-24 2022-05-13 复旦大学 一种微量外泌体捕集并计数的方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3775258A4 (en) 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
WO2021158966A1 (en) 2020-02-05 2021-08-12 Board Of Regents, The University Of Texas System Diagnostic and prognostic utility of exosomes in immunotherapy
EP4373976A4 (en) * 2021-07-20 2025-06-18 Liquid Biopsy Holdco, LLC METHODS FOR DIAGNOSIS OF DISEASE USING MICROBIAL EXTRACELLULAR VESICLE (MEV) ANALYTES

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308685A (zh) * 1998-04-01 2001-08-15 简珀恩特联合股份有限公司 核酸检测方法
CN104024430A (zh) * 2011-08-26 2014-09-03 微生物诊断有限责任公司 用于诊断和治疗心脏缺陷的方法
US20150176073A1 (en) * 2012-07-18 2015-06-25 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
US20170059572A1 (en) * 2013-12-04 2017-03-02 Board Of Regents, The University Of Texas System Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
WO2018175422A1 (en) * 2017-03-23 2018-09-27 Quadrant Biosciences Inc. Method for diagnosing or monitoring conditions characterized by abnormal temporal variations method of normalizing epigenetic data to compensate for temporal variations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101810799B1 (ko) * 2008-02-01 2017-12-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2011027956A2 (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
US20130029339A1 (en) * 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
KR101798176B1 (ko) * 2014-12-16 2017-11-15 주식회사 엠디헬스케어 세균 유래의 나노소포체를 이용한 세균성 감염질환 원인균 동정방법
KR101726488B1 (ko) * 2015-02-23 2017-04-13 이화여자대학교 산학협력단 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
US10526665B2 (en) * 2016-03-04 2020-01-07 University Of Notre Dame Du Lac Exosomal biomarkers diagnostic of tuberculosis
JP2018063182A (ja) * 2016-10-13 2018-04-19 国立大学法人 新潟大学 腸内細菌の菌叢分析方法及び被検体におけるヘリコバクター・ピロリに対するアレルギーの検出方法
KR20180076308A (ko) * 2016-12-26 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 췌장암 진단방법
WO2018124618A1 (ko) * 2016-12-26 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 췌장암 진단방법
KR101940426B1 (ko) * 2016-12-28 2019-01-18 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법
WO2018124735A1 (ko) * 2016-12-28 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308685A (zh) * 1998-04-01 2001-08-15 简珀恩特联合股份有限公司 核酸检测方法
CN104024430A (zh) * 2011-08-26 2014-09-03 微生物诊断有限责任公司 用于诊断和治疗心脏缺陷的方法
US20150176073A1 (en) * 2012-07-18 2015-06-25 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
US20170059572A1 (en) * 2013-12-04 2017-03-02 Board Of Regents, The University Of Texas System Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
WO2018175422A1 (en) * 2017-03-23 2018-09-27 Quadrant Biosciences Inc. Method for diagnosing or monitoring conditions characterized by abnormal temporal variations method of normalizing epigenetic data to compensate for temporal variations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVID C. EMERY等: "16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer’s Post-Mortem Brain", 《FRONTIERS IN AGING NEUROSCIENCE》, vol. 9, 20 June 2017 (2017-06-20), pages 1 - 13, XP055592746, DOI: 10.3389/fnagi.2017.00195 *
JIN-YOUNG PARK等: "Metagenome Analysis of Bodily Microbiota in a Mouse Model of Alzheimer Disease Using Bacteria-derived Membrane Vesicles in Blood", 《EXP NEUROBIOL》, vol. 26, no. 6, 31 December 2017 (2017-12-31), pages 369 - 379, XP055547921, DOI: 10.5607/en.2017.26.6.369 *
JIN-YOUNG PARK等: "Metagenome Analysis of Bodily Microbiota in a Mouse Model of Alzheimer Disease Using Bacteria-derived Membrane Vesicles in Blood", 《EXPERIMENTAL NEUROBIOLOGY》, vol. 26, no. 6, 31 December 2017 (2017-12-31), pages 369 - 379, XP055547921, DOI: 10.5607/en.2017.26.6.369 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114486829A (zh) * 2022-01-24 2022-05-13 复旦大学 一种微量外泌体捕集并计数的方法

Also Published As

Publication number Publication date
EP3921325A4 (en) 2022-11-23
JP2022519326A (ja) 2022-03-22
EP3921325A1 (en) 2021-12-15
KR20210125532A (ko) 2021-10-18
AU2020218358A1 (en) 2021-08-26
US20220137056A1 (en) 2022-05-05
WO2020163724A1 (en) 2020-08-13
CA3129250A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
JP5416110B2 (ja) ｉｎｖｉｖｏ細胞死を検出するためにｍｉＲＮＡを使用する方法
Li et al. Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers
Ma et al. Exosomal hsa-miR199a-3p promotes proliferation and migration in neuroblastoma
Zafar et al. Emerging biomarkers for early cancer detection and diagnosis: Challenges, innovations, and clinical perspectives
CN113631725A (zh) 用于诊断和治疗目的的对外排体相关微生物组的分离和检测
JP2010536372A5 (https=)
JP2017501694A5 (https=)
WO2012149609A1 (en) A method of diagnosing neoplasms
Tong et al. Diagnostic test to Identify Parkinson’s disease from the blood sera of Chinese population: A cross‐sectional study
Zhao et al. Analysis of the expression profile of serum exosomal lncRNA in breast cancer patients
Huang et al. CircKIAA0182-YBX1 axis: A key driver of lung Cancer progression and chemoresistance
Wu et al. MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11
Özkan et al. Human Organ Chips Reveal New Inflammatory Bowel Disease Drivers
Tataranu Liquid biopsy as a diagnostic and monitoring tool in glioblastoma
EP3889610A1 (en) Biomarker composition for predicting cancer malignant prognosis induced by microplastic exposure
CN115992226A (zh) 检测c1q表达水平的试剂在制备急性髓细胞白血病诊断或预后判断及治疗试剂中的应用
CN107583052B (zh) miR-6734-5p在制备Luminal型乳腺癌诊断工具中的应用
CN105950705B (zh) 一组microRNAs在制备阿尔兹海默氏症诊断试剂或诊断试剂盒中的应用
CN114934119A (zh) 一种结直肠癌诊断试剂盒及其应用
US11718878B2 (en) Exosome profiling for diagnosis and monitoring of vasculitis and vasculopathies including Kawasaki disease
Zhang et al. Longitudinal Monitoring of Glioblastoma Small Extracellular Vesicle Evolution Using a Nanodiagnostic to Detect Emergence of Glioma Stem Cells Driving Recurrent Disease
Xu et al. Exosomal microRNAs in Different Disease Activity Status in Systemic Lupus Erythematosus: A Retrospective Study
CN116622835B (zh) lncRNA CASC15作为肝纤维化生物标志物的应用
Kitz Role of the epithelial-to-mesenchymal transition (EMT) on circulating tumor cell (CTC) and metastasis biology in prostate cancer
WO2023154268A2 (en) A method for rapid generation of 3d organotypic cell clusters

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211109